Literature DB >> 11282009

Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution.

A C Karlsson1, M Birk, S Lindbäck, H Gaines, J E Mittler, A Sönnerborg.   

Abstract

A latent pool of HIV-1 is established early in memory CD4+ T lymphocytes and persists during antiretroviral therapy. Also, viral replication may continue in subjects despite undetectable viremia. However, it remains unclear whether this residual replication results in any significant sequence evolution. We were therefore interested in studying the viral evolution and HIV-1 DNA dynamics in subjects with primary infection receiving or not receiving early potent antiretroviral therapy. In 16 subjects, HIV-1 DNA load was monitored from 1 to 23 days, up to 1253 days, after onset of symptoms. Extensive sequential cloning and sequence analysis of the V3 region was performed in four subjects. In the treated subjects a continuous decline in the proviral load was found, corresponding to a half-life of about 6 months. As expected in newly infected individuals the founder virus populations showed high intrasubject sequence similarity. Also, a limited increase in the viral divergence was detected during the first 6 months in three treated subjects. Thereafter, no significant sequence changes were found despite analysis of a large number of clones. Our data thus suggest that early and successful therapy in compliant subjects with primary HIV-1 infection results in a highly restricted viral evolution and a decline in the proviral load close to the decay rate of human memory T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282009     DOI: 10.1089/088922201750102463

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

Review 1.  Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.

Authors:  Véronique Avettand-Fènoël; Laurent Hocqueloux; Jade Ghosn; Antoine Cheret; Pierre Frange; Adeline Melard; Jean-Paul Viard; Christine Rouzioux
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 2.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

3.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group.

Authors:  J D Stekler; R Wellman; S Holte; J Maenza; C E Stevens; L Corey; A C Collier
Journal:  Int J STD AIDS       Date:  2012-03       Impact factor: 1.359

Review 5.  Primary HIV Infection.

Authors:  Joanne Stekler; Ann C Collier
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.495

6.  Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.

Authors:  Jürgen K Rockstroh; David Asmuth; Giuseppe Pantaleo; Bonaventura Clotet; Daniel Podzamczer; Jan van Lunzen; Keikawus Arastéh; Ronald Mitsuyasu; Barry Peters; Nozza Silvia; Darren Jolliffe; Mats Ökvist; Kim Krogsgaard; Maja A Sommerfelt
Journal:  PLoS One       Date:  2019-01-30       Impact factor: 3.240

7.  Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.

Authors:  Nadine Bachmann; Chantal von Siebenthal; Valentina Vongrad; Teja Turk; Kathrin Neumann; Niko Beerenwinkel; Jasmina Bogojeska; Jaques Fellay; Volker Roth; Yik Lim Kok; Christian W Thorball; Alessandro Borghesi; Sonali Parbhoo; Mario Wieser; Jürg Böni; Matthieu Perreau; Thomas Klimkait; Sabine Yerly; Manuel Battegay; Andri Rauch; Matthias Hoffmann; Enos Bernasconi; Matthias Cavassini; Roger D Kouyos; Huldrych F Günthard; Karin J Metzner
Journal:  Nat Commun       Date:  2019-07-19       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.